Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... phenomenon. Objective: To query the association of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients ... 86 cases (66.3%) received a cytotoxic or an immunomodulating agent. In the comparison group of 172 controls (98 men [57.0%]; 74 women ...

    Research Article last updated 02/21/2017 - 10:55am.

  2. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... phenomenon. Objective   To query the association of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients ... 86 cases (66.3%) received a cytotoxic or an immunomodulating agent. In the comparison group of 172 controls (98 men [57.0%]; 74 women ...

    Research Article last updated 02/03/2017 - 1:25pm.

  3. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

    ... advanced age, still have a limited prognosis. In addition to cytotoxic chemotherapies, hypomethylating agents such as decitabine ... with decitabine not only in first-line and single-agent treatment regimens but also as second-line treatment after prior ...

    Research Article last updated 11/05/2012 - 9:34am.

  4. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... preceding MDS, myeloproliferative syndromes, leukemia due to cytotoxic chemotherapy for another condition, adverse cytogenetics or ... Patients who have received any investigational agent within 30 days prior to day 1 Women of child-bearing potential, ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.

  5. Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

    ... antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Other Name: Campath, Droxia, Fludara, Alkeran, Thiotepa Drug: ...

    Clinical Trial last updated 05/03/2016 - 10:36am.

  6. MEDALIST Trial

    ... maintained to prior ESA-containing regimen, either as single agent or combination (eg, with G-CSF); ESA regimen must have been either ... within 5 weeks prior to randomization: anticancer cytotoxic chemotherapeutic agent or treatment corticosteroid, except for ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  7. Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

    ... At least 2 weeks have elapsed since prior systemic cytotoxic chemotherapy (except intrathecal chemotherapy, hydroxyurea, ... a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to ...

    Clinical Trial last updated 06/06/2016 - 10:04am.

  8. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... until at least 2 weeks have elapsed from completion of that agent before the first dose of MEK 162. Patients must meet at least one of ... of any antineoplastic therapy within at least 4 weeks (cytotoxic chemotherapy ) or 2 weeks (biological and targeted therapy; ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  9. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... has been some response to treatment with a hypomethylating agent with a meaningful benefit (such as transfusion independence ) or a ... incorporate into RNA, and as a result it has a direct cytotoxic effect by inhibiting protein synthesis. Both drugs enter the cell and ...

    Interview last updated 06/17/2014 - 9:15am.

  10. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... failed at least two prior therapies (excluding single agent rituximab), or there is evidence of prior transformation ii. SLL or CLL ... leukemia One of the following: Cytotoxic chemotherapy , alemtuzumab , or an adequate course of ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.